[Pharmacokinetic study of intraperitoneally administered plachitin for non-curative gastrointestinal cancer].
Plachitin is a chemical compound of cis-diammine-dichloroplatinum (CDDP) and chitin. Pharmacokinetics and adverse effects of Plachitin for intraperitoneal chemotherapy (IP) were studied in 11 patients who suffered from non-curative gastrointestinal cancers in comparison with 4 patients who underwent IP of CDDP. Five patients were given 300 mg (100 mg as CDDP) of Plachitin which was cotton type on the residual cancer mass (Group A). Six patients were given IP 300 mg of Plachitin particles (Group B). As the control group, 4 patients were given IP 100 mg of CDDP (Group C). The platinum concentrations of serum, urine and intraperitoneal discharge were observed during 3-4 weeks after the treatments and calculated as the CDDP concentration. The serum CDDP levels were below 0.1 micrograms/ml for 4 weeks in Group A and B. In Group A, urine concentrations of CDDP were significantly lower than in Group B and C at 3 and 5 days after the treatment statistically (p > 0.05). But at 14 days after treatment, the urine concentration of CDDP in Group A was higher than in Group C. In Group A and B, the CDDP concentrations of intraabdominal discharge was lower than in Group C statistically (p > 0.05). Nausea was observed only in one patient of Group B and other adverse effects which contained renal sufficiency were not recognized in the three groups. Thus, Plachitin was considered an effective and safe agent for intraperitoneal chemotherapy.
Tabara
H
H
Second Dept. of Surgery, Shimane Medical University.
Kinugasa
S
S
Tachibana
M
M
Abe
S
S
Yoshimura
H
H
Suzuki
K
K
Monden
N
N
Nakamura
T
T
D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D002686:Chitin / Q000493:pharmacokinetics*; D002945:Cisplatin / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007263:Infusions, Parenteral; D018365:Neoplasm, Residual
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; C083092:plachitin; D002686:Chitin; D002945:Cisplatin